Researchers developed the first experimental mRNA-based therapy for ISG15 deficiency, a rare genetic mutation providing near-universal viral immunity, as reported on September 9, 2025.
Therapy Overview
According to a post on X by @LeonPantsulaia, the therapy targets the ISG15 deficiency mutation, which offers protection against viruses like the flu and SARS-CoV-2.
Potential Impact
The X post indicates this could enhance immunity in affected individuals.
Details from posts on X.